{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:57:19Z","timestamp":1785873439664,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s10147-025-02691-8","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T09:53:24Z","timestamp":1736243604000},"page":"593-603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphoma"],"prefix":"10.1007","volume":"30","author":[{"given":"Hiroaki","family":"Nagata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6803-5491","authenticated-orcid":false,"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoji","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsushige","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"2691_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10:74. https:\/\/doi.org\/10.1038\/s41408-020-00340-z","journal-title":"Blood Cancer J"},{"key":"2691_CR2","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A et al (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506\u20131513. https:\/\/doi.org\/10.1200\/JCO.2012.45.0866","journal-title":"J Clin Oncol"},{"key":"2691_CR3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.2017.74.1652","volume":"36","author":"S Luminari","year":"2018","unstructured":"Luminari S, Ferrari A, Manni M et al (2018) Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol 36:689\u2013696. https:\/\/doi.org\/10.1200\/JCO.2017.74.1652","journal-title":"J Clin Oncol"},{"key":"2691_CR4","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210. https:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"2691_CR5","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952. https:\/\/doi.org\/10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"2691_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, van der Jagt R, Kahl B et al (2019) First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 37:984\u2013991. https:\/\/doi.org\/10.1200\/JCO.18.00605","journal-title":"J Clin Oncol"},{"key":"2691_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377:1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"key":"2691_CR8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/jha2.904","volume":"5","author":"T W\u00e4sterlid","year":"2024","unstructured":"W\u00e4sterlid T, Dietrich CE, Oksanen A et al (2024) Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: a national population-based study. EJHaem 5:516\u2013526. https:\/\/doi.org\/10.1002\/jha2.904","journal-title":"EJHaem"},{"key":"2691_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12185-018-2497-0","volume":"108","author":"K Ohmachi","year":"2018","unstructured":"Ohmachi K, Tobinai K, Kinoshita T et al (2018) Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. Int J Hematol 108:499\u2013509. https:\/\/doi.org\/10.1007\/s12185-018-2497-0","journal-title":"Int J Hematol"},{"key":"2691_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.17219\/acem\/157290","volume":"32","author":"E Paszkiewicz-Kozik","year":"2023","unstructured":"Paszkiewicz-Kozik E, Hus I, Palka M et al (2023) Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: a real-world retrospective report of the Polish Lymphoma Research Group. Adv Clin Exp Med. 32:131\u2013136. https:\/\/doi.org\/10.17219\/acem\/157290","journal-title":"Adv Clin Exp Med."},{"key":"2691_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000807","volume":"6","author":"D Galusic","year":"2022","unstructured":"Galusic D, Basic-Kinda S, Pijuk A et al (2022) Efficacy and safety of obinutuzumab-chemotherapy combinations in front-line treatment of follicular non-hodgkin lymphoma during the COVID-19 pandemic: a study of KROHEM, the Croatian cooperative group for hematologic diseases. HemaSphere 6:e807. https:\/\/doi.org\/10.1097\/HS9.0000000000000807","journal-title":"HemaSphere"},{"key":"2691_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"2691_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"2691_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"2691_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2691_CR16","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA et al (2018) Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM Study: influence of chemotherapy on efficacy and safety. J Clin Oncol 36:2395\u20132404. https:\/\/doi.org\/10.1200\/JCO.2017.76.8960","journal-title":"J Clin Oncol"},{"key":"2691_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clml.2018.11.010","volume":"19","author":"NN Shah","year":"2019","unstructured":"Shah NN, Szabo A, Saba R et al (2019) Multicenter analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen. Clin Lymphoma Myeloma Leuk 19:95\u2013102. https:\/\/doi.org\/10.1016\/j.clml.2018.11.010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2691_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1634\/theoncologist.2017-0037","volume":"23","author":"P Mondello","year":"2018","unstructured":"Mondello P, Steiner N, Willenbacher W et al (2018) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with follicular lymphoma grade 3A: evidence from a multicenter, retrospective study. Oncologist 23:454\u2013460. https:\/\/doi.org\/10.1634\/theoncologist.2017-0037","journal-title":"Oncologist"},{"key":"2691_CR19","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1007\/s00277-020-04171-7","volume":"99","author":"M Pouyiourou","year":"2020","unstructured":"Pouyiourou M, Meyer A, Stroux A et al (2020) First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. Ann Hematol 99:2821\u20132829. https:\/\/doi.org\/10.1007\/s00277-020-04171-7","journal-title":"Ann Hematol"},{"key":"2691_CR20","doi-asserted-by":"publisher","first-page":"1120967","DOI":"10.3389\/fonc.2023.1120967","volume":"13","author":"G Margiotta-Casaluci","year":"2023","unstructured":"Margiotta-Casaluci G, Bigliardi S, Cocito F et al (2023) Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: results of a retrospective study from the Fondazione Italiana Linfomi. Front Oncol 13:1120967. https:\/\/doi.org\/10.3389\/fonc.2023.1120967","journal-title":"Front Oncol"},{"key":"2691_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/hon.3184","volume":"41","author":"ME Nizzoli","year":"2023","unstructured":"Nizzoli ME, Manni M, Ghiggi C et al (2023) Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naive advanced-stage follicular lymphoma: a subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Hematol Oncol 41:655\u2013662. https:\/\/doi.org\/10.1002\/hon.3184","journal-title":"Hematol Oncol"},{"key":"2691_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/cancers16071285","volume":"16","author":"M Bastos-Oreiro","year":"2024","unstructured":"Bastos-Oreiro M, Gutierrez A, Cabero A et al (2024) Comparing R-bendamustine vs. R-CHOP plus maintenance therapy as first-line systemic treatment in follicular lymphoma: a multicenter retrospective GELTAMO study. Cancers (Basel). 16:1285. https:\/\/doi.org\/10.3390\/cancers16071285","journal-title":"Cancers (Basel)."},{"key":"2691_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00277-022-05037-w","volume":"102","author":"Y Masamoto","year":"2023","unstructured":"Masamoto Y, Shimura A, Honda A et al (2023) Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma. Ann Hematol 102:243\u2013244. https:\/\/doi.org\/10.1007\/s00277-022-05037-w","journal-title":"Ann Hematol"},{"key":"2691_CR24","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00277-023-05306-2","volume":"102","author":"T Berger","year":"2023","unstructured":"Berger T, Shochat T, Aumann S et al (2023) Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study. Ann Hematol 102:2127\u20132136. https:\/\/doi.org\/10.1007\/s00277-023-05306-2","journal-title":"Ann Hematol"},{"key":"2691_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","volume":"27","author":"JW Friedberg","year":"2009","unstructured":"Friedberg JW, Taylor MD, Cerhan JR et al (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27:1202\u20131208. https:\/\/doi.org\/10.1200\/JCO.2008.18.1495","journal-title":"J Clin Oncol"},{"key":"2691_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/annonc\/mds429","volume":"24","author":"AK Nooka","year":"2013","unstructured":"Nooka AK, Nabhan C, Zhou X et al (2013) Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 24:441\u2013448. https:\/\/doi.org\/10.1093\/annonc\/mds429","journal-title":"Ann Oncol"},{"key":"2691_CR27","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265. https:\/\/doi.org\/10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"key":"2691_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3960\/jslrt.52.77","volume":"52","author":"A Numata","year":"2012","unstructured":"Numata A, Tomita N, Fujimaki K et al (2012) Retrospective study of the utility of FLIPI\/FLIPI2 for follicular lymphoma patients treated with R-CHOP. J Clin Exp Hematop 52:77\u201379. https:\/\/doi.org\/10.3960\/jslrt.52.77","journal-title":"J Clin Exp Hematop"},{"key":"2691_CR29","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555\u20134562. https:\/\/doi.org\/10.1200\/JCO.2008.21.3991","journal-title":"J Clin Oncol"},{"key":"2691_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM et al (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132:49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405","journal-title":"Blood"},{"key":"2691_CR31","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111\u20131122. https:\/\/doi.org\/10.1016\/S1470-2045(15)00169-2","journal-title":"Lancet Oncol"},{"key":"2691_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.V48.1.41.41","volume":"48","author":"C Shustik","year":"1976","unstructured":"Shustik C, Bergsagel DE, Pruzanski W (1976) Kappa and lambda light chain disease: survival rates and clinical manifestations. Blood 48:41\u201351","journal-title":"Blood"},{"key":"2691_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF03003191","volume":"5","author":"C Lindemalm","year":"1988","unstructured":"Lindemalm C, Christensson B, Biberfeld G et al (1988) Prognostic significance of immunoglobulin isotype expression in B-cell non-Hodgkin\u2019s lymphoma. Med Oncol Tumor Pharmacother 5:243\u2013248. https:\/\/doi.org\/10.1007\/BF03003191","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"2691_CR34","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1182\/blood.V66.6.1358.1358","volume":"66","author":"H Golomb","year":"1985","unstructured":"Golomb H, Strehl S, Oleske D et al (1985) Prognostic significance of immunologic phenotype in hairy cell leukemia: does it exist? Blood 66:1358\u20131361","journal-title":"Blood"},{"key":"2691_CR35","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","volume":"96","author":"SL Ondrejka","year":"2011","unstructured":"Ondrejka SL, Lai R, Smith SD et al (2011) Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 96:1121\u20131127. https:\/\/doi.org\/10.3324\/haematol.2010.036277","journal-title":"Haematologica"},{"key":"2691_CR36","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/bloodadvances.2018016782","volume":"2","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Muchtar E et al (2018) Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv 2:769\u2013776. https:\/\/doi.org\/10.1182\/bloodadvances.2018016782","journal-title":"Blood Adv"},{"key":"2691_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","volume":"95","author":"P Mondello","year":"2016","unstructured":"Mondello P, Steiner N, Willenbacher W et al (2016) Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study. Ann Hematol 95:1107\u20131114. https:\/\/doi.org\/10.1007\/s00277-016-2668-0","journal-title":"Ann Hematol"},{"key":"2691_CR38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/annonc\/mdw185","volume":"27","author":"K Koch","year":"2016","unstructured":"Koch K, Hoster E, Ziepert M et al (2016) Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol 27:1323\u20131329. https:\/\/doi.org\/10.1093\/annonc\/mdw185","journal-title":"Ann Oncol"},{"key":"2691_CR39","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clml.2017.07.002","volume":"17","author":"M Mustafa Ali","year":"2017","unstructured":"Mustafa Ali M, Rybicki L, Nomani L et al (2017) Grade 3 follicular lymphoma: outcomes in the Rituximab era. Clin Lymphoma Myeloma Leuk 17:797\u2013803. https:\/\/doi.org\/10.1016\/j.clml.2017.07.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2691_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000919","volume":"7","author":"W Townsend","year":"2023","unstructured":"Townsend W, Hiddemann W, Buske C et al (2023) Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study. Hemasphere 7:e919. https:\/\/doi.org\/10.1097\/HS9.0000000000000919","journal-title":"Hemasphere"},{"key":"2691_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-023-00897-5","volume":"13","author":"D Ikeda","year":"2023","unstructured":"Ikeda D, Fukumoto A, Uesugi Y et al (2023) Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease. Blood Cancer J 13:133. https:\/\/doi.org\/10.1038\/s41408-023-00897-5","journal-title":"Blood Cancer J"},{"key":"2691_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/IDR.S396271","volume":"16","author":"A Onishi","year":"2023","unstructured":"Onishi A, Matsumura-Kimoto Y, Mizutani S et al (2023) Impact of treatment with anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti-SARS-CoV-2 vaccination in mature B-cell neoplasms. Infect Drug Resist 16:509\u2013519. https:\/\/doi.org\/10.2147\/IDR.S396271","journal-title":"Infect Drug Resist"},{"key":"2691_CR43","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12185-022-03305-z","volume":"115","author":"K Narita","year":"2022","unstructured":"Narita K, Nakaji S, Tabata R et al (2022) Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol 115:728\u2013736. https:\/\/doi.org\/10.1007\/s12185-022-03305-z","journal-title":"Int J Hematol"},{"key":"2691_CR44","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"C Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N et al (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Blood 108:2540\u20132544. https:\/\/doi.org\/10.1182\/blood-2006-03-013193","journal-title":"Blood"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02691-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:49:46Z","timestamp":1740037786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02691-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02691-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TT has received honoraria from Bristol Myers Squibb (BMS), Janssen Pharmaceutical, Sanofi, Kyowa Kirin, and Chugai Pharmaceutical; TK has received honoraria from BMS, Chugai Pharmaceutical, Nippon Shinyaku, Ono Pharmaceutical, Sanofi, Nippon Kayaku, AstraZeneca, Abbvie, MSD, and Janssen Pharmaceutical; EK has received honoraria from Janssen Pharmaceutical, Chugai Pharmaceutical, Astra Zeneca, Alexion Pharmaceutical, BMS, Sanofi, Kyowa Kirin, Genmab, and Meiji Seika; NU has received honoraria from BMS, Janssen Pharmaceutical, and Abbvie; SF has received honoraria from Takeda Pharmaceutical, Sanofi, Janssen Pharmaceutical, Ono Pharmaceutical, and BMS; TF has received honoraria from Takeda Pharmaceutical; SM has received honoraria from Amgen, Astellas, Otsuka Pharmaceutical, Nippon Shinyaku, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, and BMS; YS has received honoraria from Ono Pharmaceutical, BMS, Janssen Pharmaceutical, Sanofi, Kyowa Kirin, Takeda Pharmaceutical, and Chugai Pharmaceutical. JK is a consultant for Janssen Pharmaceutical, Pfizer, Abbvie, BeiGene, and BMS; has received research funding from Kyowa Kirin, Chugai Pharmaceutical, Asahikasei, Sumitomo Pharma, Otsuka Pharmaceutical, Mochida Pharmaceutical, Taiho Pharmaceutical, and Japan Blood Products Organization; and has received honoraria from Janssen Pharmaceutical, Kyowa Kirin, Chugai Pharmaceutical, Ono Pharmaceutical, Sanofi, Pfizer, Astra Zeneca, Astellas, Eisai, Abbvie, Novartis, Daiichi Sankyo, Amgen, Otsuka Pharmaceutical, and BMS. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics committee of each participating institute approved the study. Under this approval, the need to obtain informed consent from the study subjects was waived, and we disclosed information about the survey to the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}